Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important upper GI bleeding · people admitted to intensive care units
H2 receptor antagonists probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Meters change from baseline in 6MWD · pulmonary arterial hypertension
1 finding from 1 review
Proportion of participants with improved functional class mean duration of study 16.8 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists probably leads to higher proportion of participants with improved functional class mean… compared with placebo (moderate certainty).
1 finding from 1 review
Change from baseline in BDI mean duration of study 14.3 weeks · pulmonary arterial hypertension
1 finding from 1 review
Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).
1 finding from 1 review
Change from baseline in mean PAP (mmHg) mean duration of study 17.1 weeks · pulmonary arterial hypertension
1 finding from 1 review
Change from baseline in PVR (dyn/s/cm5) mean duration of study 15.7 weeks · pulmonary arterial hypertension
1 finding from 1 review
Hepatic toxicity mean duration of study 25 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in hepatic toxicity mean duration of study 25 weeks compared with placebo (moderate certainty).
1 finding from 1 review
NFCS pain score during the procedure№ of infants: 112(2 RCTs) Score · procedural pain in neonates
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Pain score assessed up to 10 minutes after the procedure · procedural pain in neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Episodes of bradycardia · procedural pain in neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Episodes of apnea · procedural pain in neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypotension requiring medical therapy (vasopressors or fluid boluses), occurring during the procedure · procedural pain in neonates
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · chronic non‐hypovolaemic hypotonic hyponatraemia
It is very uncertain whether vasopressin receptor antagonists changes death compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Health‐related quality of life ( · chronic non‐hypovolaemic hypotonic hyponatraemia
1 finding from 1 review
Length of hospital stay · chronic non‐hypovolaemic hypotonic hyponatraemia
1 finding from 1 review
Cognitive function · chronic non‐hypovolaemic hypotonic hyponatraemia
1 finding from 1 review